Trial Profile
Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Rheumatoid Arthritis Under HUMIRA (Adalimumab) in Routine Clinical Practice (AGIL)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms AGIL
- Sponsors Abbott Laboratories; AbbVie
- 16 Jun 2018 Results assessing the treatment responses in RA patients during 5-year Adalimumab treatment (n=4283) presented at the 19th Annual Congress of the European League Against Rheumatism
- 10 Oct 2017 Status changed from recruiting to completed.
- 31 Aug 2017 Planned End Date changed from 1 Aug 2017 to 15 Sep 2017.